Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.

about

Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.

P2860

Q38745220-A66943DE-0B97-4EDD-9730-B0918FEDEC33

P2860

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.

Item

http://www.wikidata.org/entity/Q36195351

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Combined Analysis of EGFR and ...... Metastatic Colorectal Cancer.

@ast

Combined Analysis of EGFR and ...... Metastatic Colorectal Cancer.

@en

type

Item

label

Combined Analysis of EGFR and ...... Metastatic Colorectal Cancer.

@ast

Combined Analysis of EGFR and ...... Metastatic Colorectal Cancer.

@en

prefLabel

Combined Analysis of EGFR and ...... Metastatic Colorectal Cancer.

@ast

Combined Analysis of EGFR and ...... Metastatic Colorectal Cancer.

@en

P1476

Combined Analysis of EGFR and ...... Metastatic Colorectal Cancer.

@en

P2093

Gang Chen

http://www.w3.org/2001/XMLSchema#string

Jing Lin

http://www.w3.org/2001/XMLSchema#string

Xiao-jie Wang

http://www.w3.org/2001/XMLSchema#string

Yi Shi

http://www.w3.org/2001/XMLSchema#string

Yu Chen

http://www.w3.org/2001/XMLSchema#string

Yun-bin Ye

http://www.w3.org/2001/XMLSchema#string

Zeng-qing Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.

Global cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

P304

e1698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000001698

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283155172

http://www.w3.org/2001/XMLSchema#string

P698

26448020

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4616741

http://www.w3.org/2001/XMLSchema#string

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.

about

P2860

P2860

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932